NEJM: Volume 394, Issue 9 – February 26, 2026 Research

A Phase 1 clinical trial published in the Novel England Journal of Medicine on February 26, 2026, details early findings on rezatapopt, an experimental drug designed to restore function to the tumor suppressor protein p53 in cancers harboring a specific mutation. The study, appearing in Volume 394, Issue 9 of the journal, offers a first look at the drug’s safety and potential activity in patients with tumors driven by the TP53 Y220C mutation. This research represents a focused approach to targeting a common genetic alteration in cancer, but it’s crucial to understand that these are preliminary results from a small study.

Understanding the Role of p53 in Cancer

The p53 protein is often called the “guardian of the genome” because it plays a critical role in preventing cancer development. It acts as a cellular gatekeeper, detecting DNA damage and initiating processes to repair the damage or, if repair isn’t possible, triggering programmed cell death (apoptosis) to eliminate potentially cancerous cells. However, in roughly half of all human cancers, the TP53 gene – which provides the instructions for making the p53 protein – is mutated. These mutations can disable p53’s function, allowing damaged cells to proliferate unchecked.

The Y220C mutation is a specific alteration within the TP53 gene. It’s relatively common across several cancer types, including leukemia, ovarian cancer, and soft tissue sarcomas. Importantly, unlike some TP53 mutations that completely eliminate the p53 protein, the Y220C mutation often results in a misfolded, unstable p53 protein. Which means the protein is still present, but it doesn’t function properly. Rezatapopt aims to address this by stabilizing the misfolded protein, effectively “reactivating” p53’s tumor-suppressing capabilities.

Phase 1 Trial Design and Key Findings

The Phase 1 trial, conducted by researchers at multiple centers, involved 34 patients with advanced solid tumors or hematologic malignancies harboring the TP53 Y220C mutation. The primary goal of a Phase 1 trial is to assess the safety and tolerability of a new drug, and to determine the appropriate dosage. Researchers gradually increased the dose of rezatapopt to identify the maximum tolerated dose (MTD) – the highest dose that patients can receive without experiencing unacceptable side effects.

The study reported that rezatapopt was generally well-tolerated, with the most common side effects being nausea, fatigue, and decreased appetite. Several patients experienced dose-limiting toxicities, which helped define the MTD. While the primary focus was safety, the researchers too observed some evidence of anti-tumor activity in a subset of patients. Specifically, a few patients experienced stable disease – meaning their cancer didn’t grow – for extended periods. However, it’s important to note that these responses were observed in a small number of patients, and the study was not designed to definitively determine the drug’s effectiveness.

What the Results Do – and Don’t – Tell Us

The findings from this Phase 1 trial are encouraging, but they represent only a first step in the development of rezatapopt. The observed anti-tumor activity, even in a limited number of patients, suggests that reactivating p53 is a viable therapeutic strategy for cancers with the Y220C mutation. However, it’s crucial to emphasize that this study does not prove that rezatapopt is effective. Phase 1 trials are not designed to demonstrate efficacy; they are primarily focused on safety.

Several limitations should be considered when interpreting these results. The sample size was small, and the patient population was heterogeneous – meaning they had different types of cancer and varying degrees of disease severity. This makes it difficult to draw firm conclusions about the drug’s effectiveness in any specific cancer type. The study did not include a control group – patients who did not receive rezatapopt – making it impossible to determine whether the observed responses were due to the drug or other factors. The study authors acknowledge these limitations and emphasize the need for further research.

Contextualizing the Research within Existing Approaches

Targeting p53 is not a new concept in cancer research. Numerous strategies have been explored, including gene therapy to replace the mutated TP53 gene, and small molecules designed to restore p53 function. However, many of these approaches have faced challenges, including difficulties in delivering the therapeutic agent to tumor cells and overcoming the complex mechanisms that cancer cells use to evade p53’s effects. Rezatapopt’s approach of stabilizing the existing, misfolded p53 protein offers a potentially more targeted and less invasive strategy. The New England Journal of Medicine regularly publishes research on novel cancer therapies, highlighting the ongoing efforts to improve treatment outcomes.

What Comes Next: Further Clinical Trials and Research

Based on the findings from this Phase 1 trial, researchers are planning to conduct further clinical trials to evaluate rezatapopt’s effectiveness in larger and more homogeneous patient populations. These Phase 2 trials will likely focus on specific cancer types with a high prevalence of the TP53 Y220C mutation. Researchers will also investigate potential biomarkers – measurable indicators of a patient’s response to treatment – that could help identify patients who are most likely to benefit from rezatapopt. Studies are underway to explore combining rezatapopt with other cancer therapies, such as chemotherapy or immunotherapy, to enhance its anti-tumor activity. The Centers for Disease Control and Prevention (CDC) provides comprehensive information on cancer research and prevention efforts.

The development of rezatapopt, and other p53-reactivating therapies, represents a promising avenue for cancer treatment. While significant challenges remain, the early results from this Phase 1 trial offer a glimmer of hope for patients with cancers driven by the TP53 Y220C mutation. Continued research and clinical trials will be essential to determine whether this approach can ultimately improve outcomes for these patients.